首页> 外文OA文献 >Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study

【2h】

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study

机译：新诊断的胶质母细胞瘤新辅助贝伐单抗和伊立替康与贝伐单抗和替莫唑胺联合伴放化疗的Ⅱ期随机研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Hofland, Kenneth F; Hansen, Steinbjørn; Sorensen, Morten; Engelholm, Silke; Schultz, Henrik P; Muhic, Aida; Grunnet, Kirsten; Ask, Anders; Costa, Junia C; Kristiansen, Charlotte; Thomsen, Carsten; Poulsen, Hans Skovgaard; Lassen, Ulrik;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study [J] . Hofland Kenneth F., Hansen Steinbjorn, Sorensen Morten, Acta oncologica. . 2014,第1a10期

机译：新诊断的胶质母细胞瘤新辅助贝伐单抗和伊立替康与贝伐单抗和替莫唑胺联合伴放化疗的Ⅱ期随机研究
2. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma [J] . Schaefer Niklas, Proescholdt Martin, Steinbach Joachim P., Neuro-Oncology . 2018,第7期

机译：GLARIUS试验将贝伐单抗/伊立替康与替莫唑胺随机分组用于新诊断的MGMT-非甲基化胶质母细胞瘤的生活质量
3. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O-6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial [J] . Herrlinger Ulrich, Schaefer Niklas, Steinbach Joachim P., Journal of Clinical Oncology . 2016,第14期

机译：贝伐单抗加伊立替康对替莫唑胺在新诊断的O-6-甲基鸟嘌呤-DNA甲基转移酶非甲基化胶质母细胞瘤中的随机临床研究
4. Prediction of Glioblastoma Multiforme Response to Bevacizumab Treatment Using Diffusion and Perfusion Imaging [C] . Ehsan Abadi, Hamid Soltanian-Zadeh, Lisa Scarpace, Iranian Conference on Biomedical Engineering . 2015

机译：利用扩散和灌注成像预测胶质母细胞瘤对贝伐单抗治疗的响应
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme [O] . Albert Lai, Anh Tran, Phioanh L. Nghiemphu, -1

机译：贝伐单抗联合替莫唑胺在放射治疗期间和之后新诊断成胶质母细胞瘤患者的II期研究
7. Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme [O] . Lai, Albert, Tran, Anh, Nghiemphu, Phioanh L., 2011

机译：贝伐单抗联合替莫唑胺在放射治疗期间和之后新诊断成胶质母细胞瘤患者的II期研究

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study

著录项

相似文献

相关主题

期刊订阅